Original Research
Accepted on 05 May 2026
Anlotinib plus penpulimab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the perspective of the Chinese healthcare system
in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers